At what enterprise value was CARNE GROUP acquired in 2026?

During the acquisition of CARNE GROUP by PERMIRA in 2026, the company was valued at an estimated revenue multiple of 10x - 18x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of CARNE GROUP when it was acquired by PERMIRA?

The exact EV/EBITDA multiple for CARNE GROUP is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was CARNE GROUP acquired by PERMIRA?

CARNE GROUP was acquired by PERMIRA in 2026.

What was the revenue of CARNE GROUP at the time of the deal?

The revenue of CARNE GROUP at the time of the deal is estimated to be in the range of 100M - 200M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the CARNE GROUP acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the CARNE GROUP deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.irishtimes.com/business/2026/01/30/irish-funds-services-firm-carne-valued-at-14bn-by-private-equity-trade/

← DATABASE

Home Database Healthcare & PharmaCARNE GROUP

01/2026

CARNE GROUP acquired by PERMIRA

IRELAND Healthcare Services EV 1b - 4b EUR

Context

Permira has reached an agreement to acquire a significant minority stake in Carne Group. The transaction facilitates the complete exit of Vitruvian Partners (who invested in 2021) and other minority shareholders. Crucially, the founder John Donohoe, the management team, and employees will retain the majority of the capital and voting control, ensuring continuity in governance. The partnership is intended to accelerate Carne's international expansion, specifically in the United States, and to fuel further development of its digital platform.

CARNE GROUP, which reported an EBITDA margin of in 2025, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Carne Group is a leading international provider of fund management solutions, independent governance, and regulatory compliance services. It operates a hybrid model combining high-touch professional services with its proprietary technology platform, "Curator," to manage complex regulatory requirements for asset managers. In Luxembourg alone, the group oversees over EUR200bn in AuM.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2025

2024

Similar deals in Healthcare Services

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
03/2026	RADNET	GLEAMER	FRANCE	Health Tech
03/2026	THERMO FISHER SCIENTIFIC	CLARIO HOLDINGS	UNITED STATES	CRO / Clinical Trials
01/2026	SAGARD	QUIPMENT	FRANCE	Healthcare Services
01/2026	ANTIN INFRASTRUCTURE	EMSERE	NETHERLANDS	CRO / Clinical Trials
01/2026	TPG	OPTUM UK	UNITED KINGDOM	Health Tech
12/2025	PHARMA EQUITY GROUP	OTIOM	DENMARK	Health Tech
11/2025	ASKER HEALTHCARE GROUP	FINMED GROUP	FRANCE	Hospital Logistics
11/2025	EURAZEO	EXCELYA	FRANCE	CRO / Clinical Trials
10/2025	EVOLEM	APPERTON	FRANCE	Sterilization & Hygiene
05/2025	FIVE ARROWS	HUBLO	FRANCE	Health Tech

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of CARNE GROUP by PERMIRA are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: carne group

Acquirer: permira